flask 0.25 %, 0.5 %, 0.75 % Trade Names: D: Bupivacain RhGne- GB: Poulenc Rorer Carbostesin Astra Dolanaest Strathmann I: F: Marcai'ne Astra Marcai'ne adrknaline Astra-comb.. J: Marcai
Trang 1Bupheniode B 291
Phltbogel (Lipha Sant6)- I: Opino (Bayropharm)- USA: Adrin (Major); wfm
Use: antihypertensive, vasodilator RN: 22103-14-6 MF: C,,H2,I,NO2 MW 551.21 EINECS: 244-781-8
LD,: >600 mgkg (M, i.p.); >2 glkg (M, p.0.)
buphenine
(q v.)
Reference(s):
ZA 680 046 (HoudC; appl 29.12.1967; F-prior 10.1.1967,21.12.1967)
Furmulation(s): amp 4 mg, 6 mg; tabl 4 mg, 6 mg
Trade Narne(s):
F: Proclival (HoudC); wfm
Bupivacaine
(Marcain)
ATC: NOlBBOl Use: local anesthetic RN: 21 80-92-9 MF: CIRHZ8N2O MW 288.44 EINECS: 21 8-553-3
LD,,: 7100 /.~g/kg (M, i.v.);
5600 @ k g (R, i.v.)
monohydrochloride
RN: 18010-40-7 MF: C,,H,,N,O HCI MW: 324.90 EINECS: 241-917-8
pyridine- 2.6-dirnethyl- 2'.6'-picolino-
2-carbonyl aniline (1) xylidide
chloride
Trang 2292 B Bupranolol
1 -butyl-2-(2,6-dimethyl-
onilinocarbonyl)pyridinium
bromide (Ill)
onilide)
Reference(s):
DE 1 161 900 (AB Bofors; appl 19.7.1955; S-prior 6.4.1955)
DE 1 169 941 (AB Bofors; appl 19.7.1955; S-prior 28.4.1955)
GB 869 978 (AB Bofors; appl 13.2.1959; S-prior 13.3.1958)
Ekenstarn, B af et al.: Acta Chem Scand (ACHSE7) 11, 1183 (1957)
alternative syntheses:
US 2 792 399 (AB Bofors; 1957; S-prior 1954)
US 2 955 11 1 (AB Bofors; 1960; appl 1957)
Fornzulation(s): amp 0.25 %, 0.5 %: inj flask 0.25 %, 0.5 %, 0.75 %
Trade Name(s):
D: Bupivacain (RhGne- GB:
Poulenc Rorer)
Carbostesin (Astra)
Dolanaest (Strathmann) I:
F: Marcai'ne (Astra)
Marcai'ne adrknaline
(Astra)-comb
Bupranolol
Marcain (Astra) Marcam iperbarlca Marcain with Adrenaline (Pi errel)
( A s h - c o m b J: Marcain (Yoshlmotl- Bupiforan (Bieffe Medital) Takeda; as hydrochloride) Marcaina (Pierrel) IJSA: Sensocraine (Astra; as
Marcaina adrenalina hydrochloride) (Pierrel)-comb
ATC: C07AA19 Use: beta blocking agent RN: 14556-46-8 MF: CI4H,,CINO2 MW: 271.79
LD,,: 45 m g k g (M, i.v.)
CN: l-(2-chloro-5-methylphenoxy)-3-[(l,l-dimethylethyl)amino]-2-propanol
hy drochlorirle
RN: 15148-.80-8 MI?: C,4H,,C1N0,.HCl MW: 308.25 EINECS: 239-208-3
LD,,: 39.3 mg/kg (M, i.v.); 329 mglkg (M, p.0.);
15.3 mglkg (R, i.v.); 518 mglkg (R, p.0.);
438 mgkg (dog, p.0.)
Trang 3Buprenorphine B 293
glycidyl ether
Reference(s):
DE 1 236 523 (Sanol-Arzneimittel; appl 15.2.1962)
US 3 309 406 (Sanol; 14.3.1967; appl 24.3.1965)
Formulation(s): tabl 50 mg, 100 mg, 200 mg
Trade Name(s):
D: Betadrenol (Schwarz) J: Bupranolol Hydrochloride Looser (Kaken; as
F: BCtadran (J Logeais); wfm (Shin Nihon Jitsugyo; as hydrochloride)
I: Betadrenol (Schwarz) hydrochloride)
Use: analgesic RN: 52485-79-7 MF: C2,H4,NO4 MW: 467.65 EINECS: 257-950-6
LD,,: 24 mgkg (M, i.v.); 260 mglkg (M, p.0.);
31 mgkg (R, i.v.)
CN: [5a,7a(S)]-17-(cyclopropylmethyl)-a-(l,l-dimethylethyl)-4,5-epoxy-18,19-dihydr0-3-hydroxy-6- rnethoxy-a-methyl-6,14-ethenomorphinan-7-methanol
hydrochloride
RN: 53152-21-9 MF: C2,H4,N04 HCI MW: 504.1 1 EINECS: 258-396-8
thebaine
7a-acetyl-6,14-endo-
ethanotetrohydro-
thebaine (I)
methyl vinyl ketone
tert-butyl- magnesium chloride
H,C*O
7a-acetyl-6.14-endo- ethenotetrohydro- thebaine
[(IS)-1-hydroxy-1.2.2- trimethylpropyl]-
Trang 4294 B Buserelin
2 KOH, diethylene glycol 1 7 0 O C 0
2 LiAIH4, THF
1 cyclopropone-
1 brornocyan
carbonyl chloride
CHs
6.14-endo-ethano-7a- [(IS)-1-hydroxy-l,2,2- trirnethylpropylltetro- hydronorthebaine
N-cyclopropylrnethyl-6,14-
endo-ethono-7u-C(15)- 1 -
hydroxy-1 ,2,2-trirnethylpropyl]
tetrahydronortheboine (111)
KOH, diethylene glyco1.210-220 OC
Buprenorphine
i
DE 1 620 206 (Reckitt & Colman; appl 15.6.1966; GB-prior 15.6.1965)
US 3 433 791 (Reckitt & Sons Ltd; 18.3.1969; GB-prior 15.6.1965)
forr~zulation with naloxone:
EP 144 243 (Reckitt & Colman; appl 5.12.1984; GB-prior 6.12.1983)
Fonnulatior~(s): amp 0.3 mglml; sublingual tabl 0.4 pg 200 pg (as hydrochloride)
Trade Natne(s):
D: Temgesic (Roche; 1981) GB: Temgesic (Reckitt & J: Lepetan (Otsuka; 1984) F: Subutex (Schering-Plough) Colman; 1978) USA: Buprenex (Reckitt &
Temgesic (Schering- I: Temgcsic (Boehringer Colman; 1985)
Use:
L02AEO1 synthetic nonapeptidc agonist analog
of gonadorelin (LH-RH), gonad stimulating principle for treatment ol
hormone sensitive prostatic carcinoma and endometriosis RN: 57982-77-1 MF: C60H8,N,60,3 MW: 1239.45 EINECS: 261-061-9
CN: 6-[O-(I ,l-dimethylethyl)-~-serine]-9-(N-ethyl-~-prolinamide)-1O-deglycinamideluteinizing hormone- releasing factor (pig)
monoace tate
RN: 68630-75-1 MF: ChOHRhN16013 C2H402 MW: 1299.50
LD,,,: 56 m g k g (M, i.v.); >1 glkg (M, p.0.);
36 mgkg (R, i.v.); >400 mglkg (R, p.0.)
Trang 5Buserelin B 295
diacetate
RN: 59179-42-9 MF: ChOHIlhNLh013 2C2H402 MW: 1359.55
NHEt
NHEt
NHEt
NHEt
NHEt
NHEt
NHEt
NHEt
3-hydroxy-4-oxo-3,4-dihydro-1.2.3-benzotriozinyl ester
Bzl: benzyl ether OTcp: 2.4,5-trichlorophenyl ester ONSu: N-hydroxysuccinimidyl ester
N2H3: hydrozide Bu': tert-butyl ether
Reference(s):
DE 2 438 350 (Hoechst; appl 9.8.1974)
US 4 024 248 (Hoechst; 17.5.1977; D-prior 9.8.1974)
alternative synthetic methods:
DE 2 905 502 (Hoechst; appl 14.2.1979)
parenteral depot formulations:
1) microcapsules with poly-D-(-)-3-hydroxybutyric acid as carrier:
DE 3 428 372 (Hoechst; appl 1.8.1984)
EP 172 422 (Hoechst; appl 20.7.1985; D-prior 1.8.1984)
EP 262 583 (Hoechst; appl 24.9.1987; D-prior 2.10.1986, 13.12.1986)
2) with biodegradable poly(hydronyalkyl)aminodicarb~lic acid derivatives:
EP 274 127 (Hoechst; appl 29.12.1987; D-prior 3.1.1987)
Trang 6296 B Buspirone
medical use as contraceptive:
DOS 2 735 515 (Hoechst; appl 6.8.1977)
EP 764 (Hoechst; appl 1.8.1978; D-prior 6.8.1977)
Formulation(s): nasal spray 10 mg/lO ml; sol for s c amp 15 mgl10 g; sol 5.5 mgl5.5 ml for s c inj with
6.6 mg buserelin acetate on polyglycolide matrix
Trade Name(s):
D: Profact (Hoechst; 1984) Suprefact (Hoechst HoudC; I: Suprefact (Hoechst Italia)
F: Bigonist (Cassenne) GB: Suprecur (Shire)
Use: tranquilizer RN: 36505-84-7 MF: C2,H3,N502 MW: 385.51 EINECS: 253-072-2
LDS,: 136 mglkg (R, i.p.)
CN: 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
monohydrochIoride
RN: 33386-08-2 MF: C2,H,,N5O2 HCI MW: 421.97 EINECS: 251-489-4
LD,,,: 655 mglkg (M, p.0.);
196 mglkg (R, p.0.);
586 mglkg (dog, p.0.)
1 3
H \ 9
+
I-(2-pyrimidy1)-
piperozine
4-chloro- butyronitrile
+
Reference(s):
DOS 2 057 845 (Bristol-Myers; appl 24.1 1.1 970; USA-prior 24.1 1.1969)
US 3 976 776 (Mead Johnson; 24.8.1976; prior 24.1 1.1969)
Wu, Y.H eta].: J Med Chem (JMCMAR) 15,477 (1972)
US 3 907 801 (Mead Johnson; 23.9.1975; prior 24.1 1.1969)
US 3 717 634 (Mead Johnson; 20.2.1973; prior 24.1 1.1969)
Formulation(s): tabl 5 mg, 10 mg
Trade Name(s):
D: Bespar (Bristol-Myers; F: Buspar (Bristol-Myers GB: Buspar (Bristol-Myers
Trang 7Busulfan B 297 I: Axoren (Glaxo Wellcome) Buspimen (Menarini) USA: Buspar (Bristol-Myers
Busulfan ATC: LO1 ABOl
Use: antineoplastic
RN: 55-98-1 MF: C6H,406S2 MW: 246.30 EINECS: 200-250-2
LD,,: 110 mgkg (M, p.0.);
1800 p&g (R, i.v.)
CN: 1,4-butanediol dimethanesulfonate
Reference(s):
GB 700 677 (Wellcome Found.; appl 1950)
US 2 917 432 (Burroughs Wellcome; 15.12.1959; prior 5.10.1954)
Formulation(s): tabl 0.5 mg, 2 mg
Busulfan
Trade Namefs):
D: Myleran (Glaxo Wellcome) GB: Myleran (Glaxo Wellcome) J: Mablin (Takeda)
F: Misulban (Techni-Pharrna); I: Misulban (Nuovo ISM) USA: Myleran (Glaxo Wellcome)
nyl chloride
- -
Butacaine ATC: D04AB
Use: local anesthetic RN: 149-16-6 MF: C,uH3uN202 MW: 306.45 EINECS: 205-734-7
CN: 3-(dibuty1amino)-1-propanol4-aminobenzoate (ester)
monohydrochloride
RN: 5892-15-9 MF: C,,H3,N202 HCI MW: 342.91 EINECS: 227-568-4
LD5,: 21 mgkg (M, i.v.)
sulfate (2:l)
RN: 149-15-5 MF: C,,H,,N2OY 1/2H,S04 MW: 710.98 EINECS: 205-733-1
LD,,: 12 mgkg (M, i.v.)
4-nitro- 3-dibutylomino-
Trang 8298 B Butalamine
Butacaine
Referencets):
US 1 358 751 (Abbott; 1920; appl 1920)
US 1 676 470 (Abbott; 1928; GB-prior 1921)
preparation of3-dibutylarnino-1-propanol from allylalcohol and dibutylamine:
US 2 437 984 (Abbott; 1948; appl 1945)
butacaine-pamoate:
DAS 2 401 605 (Rocador; appl 14.1.1974; E-prior 18.1.1973)
Formulation(s): cps 50 mg
Trade Name(s):
F: Relaxoddi (Leurquin)- USA: Butyn Metaphen (Abbott); Butyn Sulfate (Abbott);
Use: vasodilator RN: 22131-35-7 MF: C,8H28N40 MW: 316.45 EINECS: 244-794-9
CN: N,N-dibutyl-N-(3-phenyl- 1,2,4-oxadiazol-5-y1)- 1,2-ethanediamine
hydrochloride
RN: 28875-47-0 MF: C,,H,,N,O xHC1 MW: unspecified EINECS: 249-279-2
2 2-dibutylomina-
1,2,4-oxodiazale
(cf irnolornine
synthesis)
Reference(s):
DAS 1 445 409 (J.M.D Aron-Samuel, J.J Sterne; appl 6.7.1962; GB-prior 11.7.1961, 12.6.1962)
US 3 338 899 (Aron-Samuel; 29.8.1967; prior 9.7.1962)
Formulation(s): f c tabl 40 mg, 80 mg
Trude Name(s):
D: Adrevil (Novartis) Surheme (Aron)
F: OxadilCne (Leurquin)- I: Surheme (Lipha); wfm
Trang 9Butalbital B 299
RN: 77-26-9 MF: C,,H,,N,O, MW: 224.26 EINECS: 201-017-8
LD5,: 160 mg/kg (R, s.c.)
diethyl isabutyl- molanate
Reference(s):
Volwiler, E.H.: J Am Chem Soc (JACSAT) 47,2236 (1925)
Formulation(s): f c tabl 300 mg
Trade Name(s):
Optalidon (Sandoz)-comb Fioricet (Novartis) Repan (Everett)
F: Optalidon (Sandoz)-comb Fiorinal (Novartis)-comb Sedapap (Merz)
I: Optalidon (Sandoz)-comb Fiortal wlcodeine (Genera) Tenake (Seatrace)
USA: Anolor (Blansett) Medigesic (U.S
Axocet (Savage) Pharmaceutical)
Use: antitussive RN: 18109-80-3 MF: CInH2,N0, MW: 307.43 EINECS: 242-005-2
CN: a-ethylbenzeneacetic acid 2-[2-(diethylamino)ethoxy]ethyl ester
citrate (1:l)
RN: 18 109-8 1-4 MF: C,nH2,N03 C,H,O, MW: 499.56 EINECS: 242-006-8
LD,,: 47.2 mglkg (M, i.v.); 865 mglkg (M, p.0.);
37.2 mglkg (R, i.v.); 4164 mglkg (R, p.0.)
Trang 10300 B Butanilicaine
Reference (s):
DE 1 151 51 5 (Hommel AG: appl 9.3.1 960; CH-prior 12.3.1959)
US 3 349 114 (Hommel AG; 24.10.1967; appl 17.5.1963)
Formulation(s): drops 30 mg; syrup 1.772 mg; suppos 20 mg; syrup 10.65 mg
Trade Name(s):
D: Pertix-Hommel (Hommel) Sinecod (Zyma)
Sinecod (Karlspharma) I: Butiran (Ecobi)
Sinecod (Zyma)
Use: local anesthetic RN: 3785-21-5 MF: C13HlyClN20 MW: 254.76
CN: 2-(butylamino)-N-(2-chloro-6-methylphenyl)acetamide
monohydrochloride
RN: 6027-28-7 MF: C13HlyClN20~ HCl MW: 291.22 EINECS: 227-893-1
LD,,,: 30 mglkg (M, i.v.)
phosphate (1:l)
RN: 2081-65-4 MF: C13HlyC1N20 H3P04 MW: 352.76 EINECS: 218-211-3
C I
H&-NH,
'
chloroacetyl 2-chloro-6- 2-chloro-N-(2-
chloride methylaniline chloro-6-methyl-
pheny1)acetarnide
Reference(s):
DE 939 633 (Hoechst; 1953)
DE 1 005 075 (Hoechst; 1952)
process variant:
DE 1 009 633 (Hoechst; 1953)
Formulation(s): amp 51 mgl1.7 ml; vial 1 % sol
Trade Name(s):
Butanilicaine I
D: Hostacain (Hoechst); wfm J: Hostacain (Hoechst); wfm
Use: neuroleptic RN: 653-03-2 MF: C2,H3,N30S MW: 409.60 EINECS: 211-493-9
LD,,: 67 m g k g (M, i.v.);
41 3 mglkg (R, p.0.)
CN: 1-[10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazin-2-yl]-l-butanone
diphosphate
RN: 7389-45-9 MF: CZ4H3,N30S 2H3P04 MW: 605.59 EINECS: 230-972-3